91 related articles for article (PubMed ID: 6098010)
21. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
Uhlenius N; Vuolteenaho O; Tikkanen I
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
[TBL] [Abstract][Full Text] [Related]
22. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade.
Feng TC; Ying WY; Hua RJ; Ji YY; de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):19-24. PubMed ID: 11881060
[TBL] [Abstract][Full Text] [Related]
23. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
Bing RF; Russell GI; Swales JD; Thurston H
J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368
[TBL] [Abstract][Full Text] [Related]
24. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
25. Captopril reverses the reduced vasodilator response to bradykinin in hypertensive pregnant rats.
Resende AC; Pimentel AM; de Moura RS
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):756-61. PubMed ID: 15566389
[TBL] [Abstract][Full Text] [Related]
26. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
[TBL] [Abstract][Full Text] [Related]
27. Proliferation of aortic smooth muscle cells and renin-angiotensin system in SHR rats.
Wang XY; Wu KG; Jin XQ; Wang HJ
Zhongguo Yao Li Xue Bao; 1998 Mar; 19(2):136-40. PubMed ID: 10374636
[TBL] [Abstract][Full Text] [Related]
28. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin.
Montenegro MF; Pessa LR; Tanus-Santos JE
Eur J Pharmacol; 2009 Apr; 607(1-3):173-7. PubMed ID: 19233159
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of angiotensin-converting enzyme in human hand veins.
Chalon S; Bedarida GV; Moreno H; Tejura B; Urae A; Hoffman BB; Blaschke TF
Clin Pharmacol Ther; 1999 Jan; 65(1):58-65. PubMed ID: 9951431
[TBL] [Abstract][Full Text] [Related]
30. Hypotensive effects of hemopressin and bradykinin in rabbits, rats and mice. A comparative study.
Blais PA; Côté J; Morin J; Larouche A; Gendron G; Fortier A; Regoli D; Neugebauer W; Gobeil F
Peptides; 2005 Aug; 26(8):1317-22. PubMed ID: 16042973
[TBL] [Abstract][Full Text] [Related]
31. Effect of kallikrein-kinin system activation by factor XII f pretreatment on experimental hemorrhagic shock.
Taucher M; Grässler J; Kühne H; Scheuch DW
Z Med Lab Diagn; 1990; 31(1):13-7. PubMed ID: 2330739
[TBL] [Abstract][Full Text] [Related]
32. Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III.
Pixley RA; Schapira M; Colman RW
Blood; 1985 Jul; 66(1):198-203. PubMed ID: 3873967
[TBL] [Abstract][Full Text] [Related]
33. Partial blockade of neurotensin-induced hypotension in rats by nephrectomy captopril and saralasin. Possible mechanisms.
Kérouac R; St-Pierre S; Manning M; Rioux F
Neuropeptides; 1983 Apr; 3(4):295-307. PubMed ID: 6191240
[TBL] [Abstract][Full Text] [Related]
34. Role of endogenous bradykinin in blood pressure control of conscious rats.
Waeber B; Aubert JF; Flückiger JP; Nussberger J; Vavrek RJ; Stewart JM; Brunner HR
Kidney Int Suppl; 1988 Oct; 26():S63-8. PubMed ID: 3199685
[No Abstract] [Full Text] [Related]
35. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor.
Pixley RA; Schmaier A; Colman RW
Arch Biochem Biophys; 1987 Aug; 256(2):490-8. PubMed ID: 3497611
[TBL] [Abstract][Full Text] [Related]
36. Hypotensive effects of plasma protein fraction. The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model.
Bleeker WK; Van Rosevelt RF; Ufkes JG; Loos JA; Van Mourik JA; Bakker JC
J Lab Clin Med; 1982 Oct; 100(4):540-7. PubMed ID: 6981675
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.
de Agostini A; Lijnen HR; Pixley RA; Colman RW; Schapira M
J Clin Invest; 1984 Jun; 73(6):1542-9. PubMed ID: 6725552
[TBL] [Abstract][Full Text] [Related]
38. Identification of a bradykinin-generating hypotensive substance in plasma protein fraction: prekallikrein activator (PKA-beta-Xiia).
Bakker JC; de Vries-van Rossen A; Radema H; Bleeker W; Ufkes JG; van Rosevelt RF; van Mourik JA
Adv Exp Med Biol; 1983; 156 (Pt B)():1091-7. PubMed ID: 6602466
[No Abstract] [Full Text] [Related]
39. Bradykinin-mediated hypotension after infusion of plasma-protein fraction.
Van Rosevelt RF; Bakker JC; Sinclair DM; Damen J; Van Mourik JA
J Lab Clin Med; 1982 Aug; 100(2):288-95. PubMed ID: 6980251
[TBL] [Abstract][Full Text] [Related]
40. Determination of kallikreinogen (KKN) in human plasma by activation with Hageman factor fragment (F XIIf).
Lehmann B; Taucher M; Kühne H; Scheuch DW
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):569-72. PubMed ID: 2465974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
